Cargando…

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia

BACKGROUND: There is strong association of Alzheimer’s disease (AD) pathology with gait disorder and falls in older adults without dementia. The goal of the study was to examine the prevalence and severity of AD pathology in older adults without dementia who fall and sustain hip fracture. METHODS: C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Esther S., Blennow, Kaj, Bigelow, George E., Inouye, Sharon K., Marcantonio, Edward R., Neufeld, Karin J., Rosenberg, Paul B., Troncoso, Juan C., Wang, Nae-Yuh, Zetterberg, Henrik, Sieber, Frederick E., Lyketsos, Constantine G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155555/ https://www.ncbi.nlm.nih.gov/pubmed/30252906 http://dx.doi.org/10.1371/journal.pone.0204695

Ejemplares similares

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
por: Remnestål, Julia, et al.
Publicado: (2021)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
Publicado: (2018)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

CSF T-Tau/Aβ(42) Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s Disease
por: Bendlin, Barbara B., et al.
Publicado: (2012)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
por: Meredith Jr., Jere E., et al.
Publicado: (2013)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis
por: Padovani, Alessandro, et al.
Publicado: (2022)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
por: Wellington, Henrietta, et al.
Publicado: (2018)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Delirium detection methodologies: Implications for outcome measurement in clinical trials in postoperative delirium
por: Oh, Esther S., et al.
Publicado: (2022)

Ventricular volume in relation to lumbar CSF levels of amyloid-β 1–42, tau and phosphorylated tau in iNPH, is there a dilution effect?
por: Lidén, Simon, et al.
Publicado: (2022)

Cortical microstructural associations with CSF amyloid and pTau
por: Nir, Talia M., et al.
Publicado: (2023)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
por: Nägga, Katarina, et al.
Publicado: (2018)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Tau as a fluid biomarker of concussion and neurodegeneration
por: Hossain, Iftakher, et al.
Publicado: (2022)

Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology
por: Tanabe, Sean, et al.
Publicado: (2020)

Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury
por: Hossain, Iftakher, et al.
Publicado: (2020)

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
por: Salvadó, Gemma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6450agekibkqmivcp5b0e7j224